Cellebrite DI Ltd. (NASDAQ:CLBTW) Short Interest Up 3,750.0% in January

Cellebrite DI Ltd. (NASDAQ:CLBTWGet Free Report) saw a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 15,400 shares, an increase of 3,750.0% from the January 15th total of 400 shares. Based on an average daily volume of 24,300 shares, the short-interest ratio is currently 0.6 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Cellebrite DI stock. Crescent Park Management L.P. grew its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBTWFree Report) by 3.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 549,432 shares of the company’s stock after buying an additional 17,545 shares during the quarter. Cellebrite DI comprises 0.2% of Crescent Park Management L.P.’s holdings, making the stock its 27th biggest position. Crescent Park Management L.P.’s holdings in Cellebrite DI were worth $681,000 as of its most recent filing with the Securities and Exchange Commission.

Cellebrite DI Price Performance

Cellebrite DI stock opened at $1.67 on Tuesday. The firm has a fifty day moving average of $1.44 and a 200-day moving average of $1.30. Cellebrite DI has a 52-week low of $0.67 and a 52-week high of $1.90.

About Cellebrite DI

(Get Free Report)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the United States, and the Asia-Pacific. Its DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and solutions are used in a various case, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation.

Recommended Stories

Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.